Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Figure S1-4 from COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment
View through CrossRef
<p>Figure S1 JASPAR bioinformatics software was used to analyse the human VEGF and Cyclin D1 promoter region. Figure S2. The COX-2/PGE2 axis regulates HIF-2α levels through a p-VHLmediated degradation pathway under hypoxic conditions. Figure S3 COX-2-specific inhibitors synergistically enhance the anti-tumour activity of sorafenib treatment Figure S4. The COX-2/PGE2 axis regulates HIF-2α activity to promote hepatocellular carcinoma development and reduce the sensitivity of sorafenib treatment.</p>
American Association for Cancer Research (AACR)
Title: Figure S1-4 from COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment
Description:
<p>Figure S1 JASPAR bioinformatics software was used to analyse the human VEGF and Cyclin D1 promoter region.
Figure S2.
The COX-2/PGE2 axis regulates HIF-2α levels through a p-VHLmediated degradation pathway under hypoxic conditions.
Figure S3 COX-2-specific inhibitors synergistically enhance the anti-tumour activity of sorafenib treatment Figure S4.
The COX-2/PGE2 axis regulates HIF-2α activity to promote hepatocellular carcinoma development and reduce the sensitivity of sorafenib treatment.
</p>.
Related Results
Data from COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment
Data from COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment
<div>Abstract<p><b>Purpose:</b> Hypoxia-inducible factor-2α (HIF2α) is regarded as a preferential target for individualized hepatocellular carcinoma (HCC) t...
Data from COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment
Data from COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment
<div>Abstract<p><b>Purpose:</b> Hypoxia-inducible factor-2α (HIF2α) is regarded as a preferential target for individualized hepatocellular carcinoma (HCC) t...
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
Transarterial chemoembolization plus sorafenib versus sorafenib for intermediate–advanced hepatocellular carcinoma
Transarterial chemoembolization plus sorafenib versus sorafenib for intermediate–advanced hepatocellular carcinoma
Abstract
Background:
Hepatocellular carcinoma (HCC) ranks as the sixth most common cancer and the second leading cause of cancer-related death wo...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Liposome Loaded Prostaglandin E2 (PGE2) for Muscle Regeneration
Liposome Loaded Prostaglandin E2 (PGE2) for Muscle Regeneration
Prostaglandin E2 (PGE2) is an FDA approved lipid signaling molecule for range of disorders. Also, it has a significant therapeutic potential for tissue repair and regeneration. How...
Abstract 4266: Acquired resistance to sorafenib yields CXCL12 (SDF1α) over-expression and increases invasion in hepatocarcinoma cells
Abstract 4266: Acquired resistance to sorafenib yields CXCL12 (SDF1α) over-expression and increases invasion in hepatocarcinoma cells
Abstract
Background: Sorafenib has a well known efficacy in patients with advanced hepatocellular carcinoma (HCC). Sorafenib displays antiangiogenic effects by targe...
Figure S1-4 from COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment
Figure S1-4 from COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment
<p>Figure S1 JASPAR bioinformatics software was used to analyse the human VEGF and Cyclin D1 promoter region. Figure S2. The COX-2/PGE2 axis regulates HIF-2α levels through a...